Vertex Pharma's New Drug Submission for Cystic Fibrosis Treatment Accepted for Review in Canada
Express News | Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis
Vertex Pharmaceuticals Presents Vanzacaftor/tezacaftor/deutivacaftor Data
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA at the North American Cystic Fibrosis Conference
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
